Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sipuleucel-T

View Patient Information

A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	APC8015 vaccine PA2024 (PAP/GM-CSF)-loaded dendritic cell vaccine SipT
US brand name:	Provenge
Code name:	APC 8015 APC8015

sipuleucel-T

Search NCI's Drug Dictionary